Overview

Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Compare the rate and extent of absorption of famotidine 40 mg tablets, administered as 1 x 40 mg tablet under fasting conditions.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Perrigo Company
Treatments:
Famotidine
Criteria
Inclusion Criteria:

- healthy men or women 18 years of age or older

- body mass index below 30.0 kg/m2

- willing to participate and sin a copy of the informed consent form

Exclusion Criteria:

- recent history of drug or alcohol addiction or abuse

- pregnant or lactating women

- history of allergic response to heparin, famotidine, other H2-receptor antagonists, or
other related drugs

- evidence of a clinically significant disorder or whose laboratory results were deemed
to be clinically significant

- recipient of any drugs as part of a research study within 30 days prior to study
dosing